The addition of Truqap to standard-of-care therapy improved radiographic progression-free survival in patients with ...

2024年12月16日，复旦大学脑科学研究院/脑功能与脑疾病重点实验室高艳琴教授团队联合许智祥研究员团队，在Advanced Science上 ...

Treatment options after progression on CDK4/6 inhibitors include alpelisib in combination with fulvestrant in patients with PIK3CA mutant tumors as seen in the SOLAR-1 trial, or capivasertib with ...

Mutations in PIK3CA, AKT1, and alterations in PTEN occur frequently ... of Truqap “reinforces the important role of the PI3K/AKT pathway in HR-positive breast cancer and the critical need ...

and PTEN-mutated breast cancer. So far, no AKT inhibitors have been brought to market, but several remain in clinical development. Roche's decision to drop the programme comes after AstraZeneca's ...